The use of PI3K inhibitors for the treatment of cancer is associated with a high risk for developing cutaneous adverse events, suggests a meta-analysis published in JAMA Oncology .

Conclusion In patients with melanoma or NSCLC, the clinical value of checkpoint inhibitors is evident in both RCTs and real-world settings.

More recently, third-generation agents including the non-covalent BTK inhibitors pirtobrutinib and nemtabrutinib have entered later-stage clinical development.

Objective We conducted a real-world pharmacovigilance study on psychiatric AEs with marketed ALK inhibitors in subjects with advanced NSCLC.

The addition of bone resorption inhibitors to abiraterone acetate plus prednisone is associated with improved survival outcomes in patients with metastatic castration-resistant prostate cancer and bone metastases, especially if they have high-volume disease, researchers report.

Nonmetastatic castration-resistant prostate cancer patients aged 80 years and older benefit from treatment with second-generation androgen receptor inhibitors, suggests a pooled analysis of three trials.

DOI [Teaser] Key Points The use of immune checkpoint inhibitors (ICIs) in monotherapy is associated with a lower risk of all-grade infections.

DOI [Teaser] Key Summary Points While vascular endothelial growth factor receptor (VEGFR) tyrosine kinase inhibitors (TKIs) are an essential therapeutic option in various solid tumors, post-marketing data regarding their potential cardiovascular toxicities are scant.

“Our findings indicate the need for more effective strategies to mitigate PI3K inhibitor‐associated hyperglycemia,” comment Shen and colleagues.

Treatment with androgen receptor inhibitors is associated with an increased risk for falls and fractures in men with prostate cancer, show findings from a meta-analysis.

George Sledge Jr speculates on the reasons for the contrasting results of the monarchE and PALLAS trials of adjuvant abemaciclib and palbociclib, respectively, in hormone receptor-positive, early-stage breast cancer.

Use of 5α-reductase inhibitors, typically for benign prostatic hyperplasia, may delay prostate cancer diagnosis and thus increase mortality risk, show results of a large population-based cohort study.

The combination of alpelisib and fulvestrant could be a promising option for patients with PIK3CA -mutated, hormone receptor-positive, HER2-negative advanced breast cancer who have progressed on prior CDK4/6 inhibitor and aromatase inhibitor treatment, indicate trial data.

Results of a meta-analysis suggest that treatment with interleukin inhibitors may be associated with an increased risk for cancer and infection among people with rheumatic diseases.

An analysis of the SEER–Medicare database has confirmed the link between use of 5α-reductase inhibitors, primarily for benign prostatic enlargement, and increased risk for prostate cancer-specific and all-cause mortality.

Immunotherapy with checkpoint inhibitors may raise the risk for being hospitalized with immune-related adverse events, especially in older people.

On the back of success in melanoma with PD-1 and CTLA-4 checkpoint inhibitors, attention has turned to other checkpoint proteins such as indoleamine 2,3-dioxygenase (IDO). In this editorial, Zeynep Eroglu (Moffitt Cancer Center, USA) discusses the advances and setbacks in the development of IDO inhibitors for melanoma.

Immune checkpoint inhibitor therapy is well tolerated by patients with HIV infection and advanced-stage cancer and does not appear to adversely affect HIV viral load or CD4 cell count, suggest results of a systematic data review.

A network meta-analysis has ranked the safety of immune checkpoint inhibitors in cancer treatment, with atezolizumab revealed to have the best general safety profile.

Early findings point to the antitumor efficacy of the next-generation TRK inhibitor LOXO-195 in patients with NTRK fusion-positive cancers and NTRK resistance mutations acquired during treatment with first-generation agents.